quinoxalines has been researched along with carbamates in 225 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (4.00) | 18.7374 |
1990's | 1 (0.44) | 18.2507 |
2000's | 2 (0.89) | 29.6817 |
2010's | 147 (65.33) | 24.3611 |
2020's | 66 (29.33) | 2.80 |
Authors | Studies |
---|---|
Ferrando, R; Raynaud, JP; Spanoghe, JP; Truhaut, R | 1 |
Brun, GL; Mallet, V; Surette, D | 1 |
Curley, JE; Gonci, DA; Goras, JT; Gordon, PN; Murai, K | 1 |
Babcock, WE; Chalquest, RR; Rainier, RH; Thrasher, GW | 2 |
Holder, JM; Sinclair, AN | 1 |
Burrell, RA; Cox, JM; Savins, EG | 1 |
Harrington, R; Hooper, BE; Troutt, HF | 1 |
Raynaud, JP | 1 |
Carter, DB; Im, WB; Sethy, VH; Tang, AH; TenBrink, RE | 1 |
Barnes, NY; Parent, AT; Sisodia, SS; Taniguchi, Y; Thinakaran, G | 1 |
Kovacs, FE; Szabo, B; Urbanski, MJ | 1 |
Lilja, AM; Marutle, A; Nordberg, A; Porras, O; Storelli, E | 1 |
Baudot, R; Cren-Olivé, C; Feidt, C; Fratta, C; Lazartigues, A; Thomas, M; Wiest, L | 1 |
Burlein, C; Carroll, SS; Claudio, G; Coleman, PJ; Di Filippo, M; Dimuzio, JM; Fandozzi, C; Ferrara, M; Gates, AT; Graham, DJ; Harper, S; Hazuda, DJ; Huang, Q; Liverton, NJ; Ludmerer, SW; McCauley, JA; McHale, C; Monteagudo, E; Olsen, DB; Pucci, V; Rowley, M; Rudd, MT; Soriano, A; Stahlhut, MW; Summa, V; Vacca, JP | 1 |
Ban, Y; Liu, H; Xue, W; Yao, X | 1 |
Beutner, G; Dreher, SD; Humphrey, G; Kim, M; Kuethe, J; Linn, K; Marcune, B; Pei, T; Yasuda, N; Zhong, YL | 1 |
Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I; Zappulo, E | 1 |
Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J | 1 |
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
Barnard, RJ; Black, S; Caro, L; Curry, S; DiNubile, MJ; Gilbert, C; Howe, AY; Hwang, PM; Liu, R; Ludmerer, SW; Mobashery, N; Newhard, W; Nickle, D | 1 |
Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E | 1 |
Alric, L; Balart, L; Barr, E; Bronowicki, JP; Dutko, F; Gane, E; Ghalib, R; Ghesquiere, W; Guyader, D; Haber, B; Howe, AY; Hwang, P; Lagging, M; Lawitz, E; Lester, L; Pearlman, B; Robertson, M; Shaughnessy, M; Sievert, W; Sund, F; Tam, E; Wahl, J | 1 |
Cornberg, M; Manns, MP | 1 |
Barr, E; Buti, M; Calleja, JL; DiNubile, MJ; Forns, X; Gilbert, C; Gordon, SC; Hofer, H; Howe, AY; Lawitz, E; Palcza, J; Robertson, MN; Wahl, J; Zuckerman, E | 2 |
Barr, E; Ben Ari, Z; Brown, DD; Butterton, JR; DiNubile, MJ; Ghalib, R; Nguyen, BY; Pockros, PJ; Reddy, KR; Robertson, MN; Wahl, J; Wan, S; Zeuzem, S; Zhao, Y | 1 |
Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H | 1 |
Brown, A; Gendrano, IN; Howe, A; Hwang, P; Lagging, M; Mantry, PS; Mobashery, N; Ramji, A; Robertson, M; Vierling, JM; Wahl, J; Weilert, F; Zhang, B | 1 |
Bukh, J; Gottwein, JM; Humes, DG; Jensen, SB; Li, YP; Ramirez, S; Serre, SB | 1 |
Barr, E; Bloch, M; Gress, J; Katlama, C; Klopfer, S; Lalezari, J; Mallolas, J; Matthews, GV; Nelson, M; Nguyen, BY; Orkin, C; Platt, HL; Robertson, MN; Rockstroh, JK; Saag, MS; Shaughnessy, M; Sulkowski, M; Wahl, J; Zamor, PJ | 1 |
Barr, E; Bruchfeld, A; Greaves, W; Hassanein, T; Jackson, B; Liapakis, A; Londoño, MC; Martin, P; Monsour, H; Nelson, DR; Nguyen, BY; Pol, S; Robertson, M; Roth, D; Silva, M; Wahl, J; Wan, S; Zamor, PJ; Zuckerman, E | 1 |
Hubbard, H; Lawitz, E; Vizuete, J | 1 |
Ali, A; Aydin, C; Kurt Yilmaz, N; Prachanronarong, KL; Schiffer, CA; Soumana, DI | 1 |
Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
Nelson, DR; Peter, J | 1 |
Gordon, SC; Jafri, SM; Sulejmani, N | 1 |
Cope, R; Friedman, ML; Sorbera, MA | 1 |
Asante-Appiah, E; Black, T; Bystol, K; Chase, R; Curry, S; Hazuda, D; Howe, AY; Ingravallo, P; Lahser, FC; Liu, R; McMonagle, P; Xia, E | 1 |
Alric, L; Bonnet, D | 1 |
Borgia, G; Buonomo, AR; Gentile, I; Pinchera, B; Scotto, R; Zappulo, E | 1 |
Keating, GM | 1 |
Park, SH | 1 |
Warparkowski, A | 1 |
Zimmermann, W | 1 |
Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y | 1 |
Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E | 1 |
Saab, S; Suraweera, D; Weeratunga, AN | 1 |
Beavers, K; Bernstein, D; Brainard, DM; Chung, RT; Davis, M; Dvory-Sobol, H; Etzkorn, K; Everson, G; Gane, EJ; Gordon, SC; Khalid, O; Kowdley, KV; Kwo, PY; Lu, S; McHutchison, JG; Nguyen, MH; Poulos, JE; Pound, D; Rodriguez-Torres, M; Stamm, LM; Stedman, CA; Tong, M; Tsai, N; Yang, JC | 1 |
Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z | 1 |
Andreone, P; Gamal, N | 1 |
Bagchi, S; Kottilil, S; Papudesu, C | 1 |
Alric, L; Kamar, N; Rostaing, L | 1 |
Barr, E; Black, S; Buti, M; Dutko, FJ; Gane, EJ; Gress, J; Haber, B; Kwo, P; Lin, L; Lupinacci, L; Pearlman, B; Peng, CY; Robertson, M; Serfaty, L; Shafran, S; Stryszak, P; Vierling, JM; Wahl, J | 1 |
Barr, E; Dutko, FJ; Evans, B; Gutierrez, JA; Haber, B; Howe, A; Huang, HC; Hwang, P; Landaverde, CE; Lawitz, E; Li, JJ; Poordad, F; Robertson, M; Wahl, J; Wells, JT | 1 |
Black, S; Caro, L; Chayama, K; Fujimoto, G; Itoh, Y; Iwasa, T; Karino, Y; Kawada, N; Kumada, H; Mochida, S; Okanoue, T; Robertson, MN; Suzuki, Y; Takaki, S; Toyoda, H; Wahl, J; Yatsuzuka, N; Yodoya, E; Yoshiji, H | 1 |
Elbasha, EH; Nwankwo, C; Robertson, MN | 1 |
Elbasha, E; Greaves, W; Nwankwo, C; Roth, D | 1 |
Chen, H; Huang, P; Li, J; Liu, M; Wang, J; Yao, Y; Yu, R; Yue, M; Zang, F; Zhang, Y | 1 |
Barr, E; Haber, BA; Hézode, C; Howe, AYM; Hwang, P; Jacobson, IM; Kwo, PY; Lawitz, E; Peng, CY; Robertson, M; Wahl, J | 1 |
Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y | 1 |
Lim, SG | 1 |
Asante-Appiah, E; Black, S; Chase, R; Curry, S; Guo, Z; Hu, Y; Ingravallo, P; McMonagle, P | 1 |
Butterton, JR; Caro, L; Feng, HP; Guo, Z; Huang, X; Ma, J; Mangin, E; Marshall, WL; O'Reilly, TE; Panebianco, D; Talaty, J; Yeh, WW | 1 |
Barr, E; Ben-Ari, Z; Bourlière, M; Chase, R; Colombo, M; Haber, B; Hézode, C; Hwang, P; Lee, WM; Marco, VD; Morgan, L; Nguyen, BY; Qiu, J; Robertson, M; Spengler, U; Strasser, SI; Talwani, R; Wahl, J | 1 |
Alston, S; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Reau, N; Reddy, KR; Reeve, B; Sarkar, S; Sterling, RK; Stewart, P | 1 |
Agarwal, K; Asselah, T; Berg, T; Bhandari, BR; Borgia, SM; Brainard, DM; Bräu, N; Davis, M; Dore, GJ; Dvory-Sobol, H; Feld, JJ; Foster, GR; Gane, EJ; Hyland, RH; Jacobson, IM; Lawitz, E; McHutchison, JG; Nahass, RG; Pearlman, B; Roberts, SK; Ruane, PJ; Shafran, SD; Stamm, LM; Stedman, CAM; Subramanian, GM; Svarovskaia, E; Thompson, AJ; Willems, BE; Workowski, KA; Zhu, Y | 1 |
Asante-Appiah, E; Barr, E; Gane, E; Haber, B; Hwang, P; Luketic, V; Nahass, R; Robertson, M; Wahl, J | 1 |
Bansal, MB; Bourlière, M; Brainard, DM; Buggisch, P; Cooper, CL; Curry, MP; de Lédinghen, V; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Huang, KC; Hyland, RH; Kowdley, KV; Landis, CS; Manns, MP; McHutchison, JG; Pianko, S; Ramji, A; Ravendhran, N; Reddy, KR; Schiff, ER; Stamm, LM; Strasser, SI; Subramanian, GM; Svarovskaia, E; Tong, M; Tran, TT; Verna, EC; Vierling, JM; Younes, ZH; Zeuzem, S; Zhang, J | 1 |
Arduino, JM; Barr, E; Bruchfeld, A; Greaves, W; Hwang, P; Londoño, MC; Martin, P; Monsour, H; Nelson, DR; Nguyen, BY; Pol, S; Robertson, M; Roth, D; Silva, M; Wahl, J | 1 |
Hussar, DA | 2 |
Cheng, PN; Chiu, YC; Sun, HY; Tsai, WJ; Tseng, CY; Young, KC | 1 |
Jacobson, IM; Voaklander, R | 1 |
Asante-Appiah, E; Iwasa, T; Kinoshita, K; Nakamura, K | 1 |
Arias, A; Barreiro, P; Benítez-Gutiérrez, L; Carrasco, I; de Mendoza, C; Peña, JM; Soriano, V | 1 |
Almasio, PL; Barr, E; Bruno, S; Buti, M; Butterton, JR; Dutko, FJ; Fernsler, D; Gao, W; Grandhi, A; Hassanein, TI; Huang, HC; Jancoriene, L; Lawitz, E; Li, JJ; Liu, H; Muellhaupt, B; Nguyen, BT; Pearlman, B; Plank, RM; Robertson, MN; Ruane, PJ; Shepherd, A; Su, FH; Tannenbaum, B; Vierling, JM; Wahl, J; Wan, S; Yeh, WW; Yoshida, EM | 1 |
Agarwal, K; Barr, E; Ben-Ari, Z; Butterton, JR; Chen, HL; Dutko, FJ; Esteban, R; Fernsler, D; Fitzgerald, B; Foster, GR; Gane, EJ; Gao, W; Gerstoft, J; Grandhi, A; Huang, HC; Laursen, AL; Li, JJ; Liu, H; Nguyen, BT; Pianko, S; Plank, RM; Roberts, SK; Robertson, MN; Su, FH; Thompson, AJ; Wahl, J; Wan, S; Yeh, WW; Zeng, Z; Zeuzem, S; Zuckerman, E | 1 |
Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Olemy, A | 1 |
Arends, JE; Brinkman, K; Burger, DM; Dofferiiof, ASM; Reiss, P; Rijnders, B; Smit, C; Smolders, EJ; T M M de Kanter, C; van der Valk, M | 1 |
Angus, P; Butterton, JR; Caro, L; Fandozzi, C; Fraser, IP; Gane, E; Guo, Z; Ho, M; Iwamoto, M; Marbury, T; Panebianco, D; Reitmann, C; Smith, WB; Talaty, J; Uemura, N; Wenning, L; Yeh, WW | 1 |
Alves, K; Atarashi, T; Burroughs, M; Chayama, K; Eguchi, Y; Karino, Y; Kato, K; Kawakami, Y; Krishnan, P; Kumada, H; Naganuma, A; Oberoi, RK; Pilot-Matias, TJ; Pugatch, DL; Redman, R; Sato, K; Seike, M; Suzuki, F; Takei, Y; Watanabe, T; Xie, W; Yoshiji, H | 1 |
Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K | 1 |
Aschenbrenner, DS | 1 |
Alric, L; Bellissant, E; Bourlière, M; de Lédinghen, V; Gibowski, S; Hézode, C; Jézéquel, C; Laforest, C; Larrey, D; Métivier, S; Pailhé, A; Pawlotsky, JM; Pol, S; Renault, A; Samuel, D; Tran, A; Tual, C; Zoulim, F | 1 |
Kottilil, S; O'Brien, TR; Pfeiffer, RM | 1 |
Chahine, EB; Childs-Kean, LM; Kelley, D | 1 |
Badshah, C; Barr, E; Brown, A; Durkan, C; Foster, GR; Haber, B; Hézode, C; Lahser, F; Roberts, SK; Robertson, M; Wahl, J; Zekry, A; Zhang, B; Zuckerman, E | 1 |
Bourliere, M; Cooper, C; Flamm, S; Gordon, S; Hunt, S; Jacobson, I; Kowdley, K; Mann, MP; Reddy, KR; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
Asselah, T; Foster, GR; Gane, EJ; Henry, L; Jacobson, IM; Lawitz, E; Pearlman, B; Racila, A; Roberts, SK; Stepanova, M; Thompson, AJ; Welzel, TM; Willems, BE; Younossi, I; Younossi, ZM | 1 |
Besandre, R; Liu, HW | 1 |
Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Garrett, G; Huang, X; Iwamoto, M; Lasseter, KC; Liu, F; Marbury, T; Marshall, WL; Panebianco, D; Preston, RA; Wenning, L; Yeh, WW | 1 |
Younossi, ZM | 1 |
Danta, M; Sanagapalli, S | 1 |
Barr, E; Cheng, W; George, J; Hwang, P; Kumada, H; Platt, H; Robertson, M; Serfaty, L; Sperl, J; Strasser, S; Talwani, R; Vierling, J; Wahl, J; Zeuzem, S | 1 |
Asatryan, A; Asselah, T; Bourlière, M; Bruck, R; Chuang, WL; Dore, GJ; Feld, JJ; Felizarta, F; Flamm, S; Flisiak, R; Foster, GR; Fu, B; Fuster, F; Gane, E; Kaita, K; Kort, J; Kwo, P; Lin, CW; Liu, R; Mensa, FJ; Ng, TI; Paik, SW; Pilot-Matias, T; Pol, S; Poordad, F; Puoti, M; Roberts, SK; Ruane, PJ; Sepulveda-Arzola, G; Soto-Malave, R; Stedman, CA; Tam, E; Trinh, R; Vargas, HE; Vierling, J; Wang, S; Wedemeyer, H; Zeuzem, S | 1 |
Asante-Appiah, E; Asselah, T; Barr, E; de Ledinghen, V; Gerstoft, J; Hwang, P; Nguyen, BY; Pockros, PJ; Reesink, H; Robertson, M; Serfaty, L; Talwani, R; Wahl, J | 1 |
Bair, N; Bowring, MG; Brown, DM; Chattergoon, MA; Desai, NM; Durand, CM; Massaccesi, G; Naqvi, FF; Ostrander, D; Reyad, A; Segev, DL; Sugarman, J; Sulkowski, M; Wesson, R | 1 |
Abergel, A; Clément, A; Di Martino, V; Durand-Zaleski, I; Levy-Bachelot, L; Maunoury, F; Nwankwo, C; Thervet, E | 1 |
Deeks, ED; Heo, YA | 1 |
Cory, TJ; Gong, Y; Kodidela, S; Kumar, S; Mu, Y | 1 |
Cheung, TT; Feng, HP; Li, W; Ling Lam, KS; Mu, S; Wang, J; Wang, Z; Yan Chiu, JW; Yeh, WW; Yuen, MF; Yung Cheung, BM; Zhao, XM | 1 |
Abe, H; Asano, T; Atsukawa, M; Deguchi, A; Fujioka, S; Hiraoka, A; Iio, E; Ishikawa, T; Itobayashi, E; Iwakiri, K; Kato, K; Kondo, C; Kumada, T; Masaki, T; Michitaka, K; Mikami, S; Moriya, A; Ogawa, C; Okubo, H; Okubo, T; Senoh, T; Shimada, N; Tada, T; Takaguchi, K; Tamai, H; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsuji, K; Uojima, H; Watanabe, T; Yoneyama, H | 1 |
Caroleo, B; Colangelo, L; De Sarro, G; Gallelli, L; Perticone, M | 1 |
Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Dosoky, M; El-Olemy, A | 1 |
Cao, Y; El-Serag, HB; Erickson, KF; Kanwal, F; Kramer, JR; Puenpatom, A; Smith, D | 1 |
Waked, I | 1 |
Bourlière, M; Brainard, DM; Curry, MP; Dvory-Sobol, H; Gordon, SC; Hyland, RH; Landis, CS; Manns, MP; McHutchison, JG; Ravendhran, N; Reddy, KR; Schiff, ER; Sepe, TE; Serfaty, L; Stamm, LM; Subramanian, GM; Thompson, AJ; Tran, TT; Zhang, J | 1 |
Summers, BB | 1 |
Bourliere, M; Gordon, SC; Manns, MP; Racila, A; Reddy, R; Schiff, E; Stepanova, M; Tran, T; Younossi, I; Younossi, ZM | 1 |
Attar, BM; Gandhi, S; Jaiswal, P; Szynkarek, R; Ton, L; Yap, JE | 1 |
Bloom, RD; Potluri, VS | 1 |
Flamm, SL | 1 |
Occhipinti, V; Rumi, MG | 1 |
Arrais de Castro, R; Borges-Costa, J; Tato Marinho, R; Vilas, P | 1 |
Bourliere, M; Brainard, DM; Camus, G; Cooper, CL; Doehle, BP; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Hyland, RH; Kowdley, KV; Manns, MP; Martin, R; Mo, H; Reddy, KR; Roberts, SK; Sarrazin, C; Stamm, LM; Svarovskia, E; Zeuzem, S | 1 |
Béguelin, C; Bernasconi, E; Böni, J; Braun, DL; Conen, A; Delaloye, J; Fehr, JS; Flepp, M; Günthard, HF; Hampel, B; Kouyos, R; Künzler-Heule, P; Nguyen, H; Nicca, D; Rauch, A; Rougemont, M; Schmid, P; Shah, C; Stöckle, M | 1 |
Sulkowski, MS | 1 |
Ali, A; Huang, W; KurtYilmaz, N; Leidner, F; Matthew, AN; Newton, A; Petropoulos, CJ; Schiffer, CA | 1 |
Agrawal, S; Asante-Appiah, E; Black, S; Bystol, K; Carr, D; Chase, R; Curry, S; Ferrari, E; Ingravallo, P; Kozlowski, J; Lahser, F; Liu, R; McMonagle, P; Rokosz, L; Tong, L; Yu, W | 1 |
Chen, P; Liu, Q; Ma, A | 1 |
Kottilil, S; Mathur, P; Wilson, E | 1 |
Morikawa, K; Nakamura, A; Sakamoto, N; Shimazaki, T | 1 |
Hinds, AE; Pearlman, BL | 1 |
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K | 1 |
Devine, P; Kim, J; Waldman, J; Wang, T; Xu, F | 1 |
Altice, FL; Barr, E; Haber, B; Hwang, P; Jacobson, I; Robertson, M; Rockstroh, J; Serfaty, L | 1 |
Bondin, M; Cacoub, P; Fabrizi, F; Negro, F | 1 |
Cenderello, G; Di Biagio, A; Taramasso, L | 1 |
Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Fraser, I; Guo, Z; Huang, X; Iwamoto, M; Jumes, P; Ma, J; Mangin, E; Marshall, WL; Panebianco, D; Ross, LL; Talaty, J; Yeh, WW | 1 |
Baba, M; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
Ammerlaan, HSM; Arends, JE; Bierman, WF; Boerekamps, A; Claassen, MAA; De Weggheleire, A; den Hollander, J; Dofferhoff, ASM; Florence, E; Hullegie, SJ; Kootstra, GJ; Lauw, FN; Leyten, EM; Popping, S; Posthouwer, D; Rijnders, BJA; Schinkel, J; Soetekouw, R; van de Vijver, DACM; van den Berk, GE; van Kasteren, ME | 1 |
Martinello, M; Matthews, GV | 1 |
Brainard, DM; Dvory-Sobol, H; Gane, EJ; Hyland, RH; Nyberg, L; Ruane, P; Shafran, S; Shao, J; Stamm, LM; Strasser, SI; Tran, T | 1 |
Botejue, A; Devine, PN; Forte, J; Huffman, MA; Kassim, AM; Kim, T; McIntosh, JA; Rozzell, D; Zhang, C | 1 |
Bhagunde, P; Butterton, JR; Caro, L; Du, L; Fandozzi, C; Feng, HP; Guo, Z; Iwamoto, M; Marshall, WL; Panebianco, D; Wenning, L; Yeh, WW | 1 |
Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV | 1 |
Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
Abt, PL; Acker, M; Atluri, P; Bar, KJ; Bermudez, C; Bloom, RD; Blumberg, EA; Gentile, C; Goldberg, DS; Goldberg, LR; Hasz, R; Hornsby, N; Levine, MH; McLean, RC; Porrett, P; Reddy, KR; Reese, PP; Sicilia, A; Smith, J; Suplee, L; Van Deerlin, VM; Woodards, A; Zahid, MN | 1 |
Ankrom, W; Fan, L; Iwamoto, M; Khalilieh, S; Mitra, P; Sanchez, RI; Sterling, LM; Stoch, SA; Triantafyllou, I; Wolford, D; Yee, KL | 1 |
Bhanja, S; Caro, L; Charles, ED; Everson, GT; Firpi-Morell, R; Hwang, P; Jacobson, IM; Platt, H; Poordad, F; Robertson, M; Verna, EC | 1 |
Bukh, J; Dietz, J; Fahnøe, U; Filskov, J; Fourati, S; Ghanem, L; Gottwein, JM; Humes, D; Jensen, SB; Krarup, H; Pawlotsky, JM; Pedersen, MS; Pham, LV; Pihl, AF; Ramirez, S; Sarrazin, C; Schønning, K; Serre, SBN; Sølund, CS; Tang, Q; Weis, N | 1 |
Pawlotsky, JM | 1 |
Aghemo, A; Parigi, TL; Torres, MCP | 1 |
Angulo-Diaz, V; Lim, JK; Mandimika, C; Maughan, A; Ogbuagu, O; Sadigh, K; Villanueva, M | 1 |
Hinds, A; Pearlman, B; Perrys, M | 1 |
Amador, J; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Rajender Reddy, K; Reau, N; Reeve, BB; Sarkar, S; Serper, M; Sterling, RK; Stewart, PW | 1 |
Colace, T; Dewitt, K; Hermans, A; Kesisoglou, F; Marota, M; Xu, W | 1 |
Chung, WJ; Haber, B; Heo, J; Hwang, P; Kim, DY; Kim, YJ; Kulasingam, S; Lee, YJ; Paik, SW; Sim, E; Tak, WY; Talwani, R | 1 |
Appleby, T; Barauskas, O; Chan, K; Cheng, G; Jin, D; Karki, KK; Katana, A; Kato, D; Kobayashi, T; Link, JO; Martinez, R; Ramey, K; Sangi, M; Schrier, A; Schultz, BE; Siegel, D; Taylor, JG; Tran, CV; Villaseñor, AG; Vivian, R; Wang, K; Wang, Y; Yang, CY; Yang, ZY; Zablocki, J; Zipfel, S | 1 |
Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E | 1 |
Cooke, G; Fawsitt, CG; Vickerman, P; Welton, NJ | 1 |
Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J | 1 |
Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A | 1 |
Antón, JJ; Arenas, JI; Bernal, E; Casado, M; Chueca, N; Collado, A; De la Iglesia, A; Espinosa, MD; García, F; García-Bujalance, S; García-Deltoro, M; García-Herola, A; Hernández-Quero, J; Hidalgo-Tenorio, C; Lozano, AB; Macías, J; Martínez, O; Omar, M; Pascasio, JM; Pérez, AB; Pineda, JA; Rincón, P; Ríos, MJ; Rivero-Juárez, A; Rosales, JM; Salmerón, J; Santos, J; Selfa, A; Téllez, F; Vélez, M; Von-Wichmann, MÁ | 1 |
Alcantarini, C; Angelini Zucchetti, T; Bargiacchi, O; De Carlis, L; Ferla, F; Lauterio, A; Merli, M; Puoti, M; Rossotti, R; Travi, G | 1 |
Cariti, G; Di Perri, G | 1 |
Cheng, PN; Liu, CJ; Lo, CC; Tseng, IH; Tseng, KC | 1 |
Chen, J; Chen, L; Lu, M; Stämpfli, A | 1 |
Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Blaszkowska, M; Buczyńska, I; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D | 1 |
Ahmed, SNS; Alric, L; Asante-Appiah, E; Asselah, T; Bronowicki, JP; Brown, D; Guidoum, A; Haber, BA; Hagen, K; Hall, JD; Hanna, GJ; Hezode, C; Hwang, P; Larrey, D; Leroy, V; Loustaud-Ratti, V; Nguyen-Khac, E; Ozenne, V; Pol, S; Robertson, MN; Serfaty, L; Su, FH; Talwani, R; Tran, A | 1 |
Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawaoka, T; Morio, K; Murakami, E; Nakahara, T; Ohya, K; Tsuge, M; Yamauchi, M | 1 |
Bukh, J; Fernandez-Antunez, C; Li, YP; Mikkelsen, LS; Pedersen, J; Ramirez, S | 1 |
Deshayes, E; Fersing, C; Guiu, B; Meunier, L; Quenet, F | 1 |
Choi, DT; El-Serag, HB; Erickson, KF; Kanwal, F; Kramer, JR; Puenpatom, A; Yu, X | 1 |
Ali, A; Henes, M; Hou, S; Kosovrasti, K; Kurt Yilmaz, N; Leidner, F; Schiffer, CA; Timm, J | 1 |
Al-Ahmed, SH; Aldrazi, FA; Alfouzan, WA; Alsuliman, SA; Bazzi, AM; Haque, S; Rabaan, AA | 1 |
Chung, RT; Holmes, JA | 1 |
Guyader, D; Jézéquel, C; Lalanne, S; Lemaitre, F; Mercerolle, M; Pronier, C; Tron, C; Verdier, MC | 1 |
Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX | 1 |
Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P | 1 |
Chen, J; Lei, P; Li, G; Li, Y | 1 |
Boyd, A; Chas, J; Chevaliez, S; Girard, PM; Lacombe, K; Miailhes, P; Peytavin, G; Pialoux, G; Piroth, L; Rosenthal, E; Rougier, H; Valantin, MA; Yazdanpanah, Y | 1 |
Cornberg, M; Guenther, V; Heyne, R; Hinrichsen, H; John, C; Klinker, H; Martin, K; Simon, KG; Stoehr, A; Witte, V; Zeuzem, S | 1 |
Barash, D; Chayama, K; Churkin, A; Cotler, SJ; Dahari, H; Dasgupta, S; Etzion, O; Gorstein, E; Imamura, M; Nakahara, T; Tsuge, M; Uprichard, SL; Yardeni, D | 1 |
Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A | 1 |
Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C | 1 |
Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ | 1 |
Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B | 1 |
Abbink, EJ; Burger, DM; Colbers, A; Drenth, JPH; Pijnenburg, DWM; van Seyen, M | 1 |
Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
Brown, DD; Haber, BA; Klopfer, SO; Kwo, P; Nangia, G; Reddy, KR; Robertson, MN; Vierling, JM | 1 |
Claar, E; Coppola, N; De Pascalis, S; Fraia, AD; Messina, V; Minichini, C; Occhiello, L; Pisaturo, M; Sangiovanni, V; Starace, M | 1 |
Bhowmik, D; Jagadeesan, R; Kumar, D; Kumar, N; Nandi, R; Prakash, A | 1 |
Ali, HN; Farooq, S; Iftikhar, H; Naveed, H; Shahzad-Ul-Hussan, S | 1 |
Rodriguez-Reyes, M; Ruiz-Boy, S; Sotoca-Momblona, JM | 1 |
Deguchi, A; Fujita, K; Himoto, T; Iwama, H; Kobara, H; Masaki, T; Mimura, S; Morishita, A; Nakahara, M; Nomura, T; Oryu, M; Oura, K; Sakamoto, T; Shimotohno, K; Tadokoro, T; Takuma, K; Tani, J; Tsutsui, K; Wakita, T; Yoneyama, H | 1 |
Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A | 1 |
Avihingsanon, A; Chayanupatkul, M; Chittmittraprap, S; Chuaypen, N; Pratedrat, P; Tangkijvanich, P | 1 |
Chen, YC; Cheng, YT; Chien, RN; Hsieh, YC; Jeng, WJ; Lin, CY; Liu, YC; Sheen, IS; Teng, W | 1 |
Cornberg, M; Deterding, K; Jung, MC; Klinker, H; Manns, MP; Sarrazin, C; Schulze Zur Wiesch, J; Serfert, Y; Simon, KG; Stoehr, A; Teuber, G; Vermehren, J; Wedemeyer, H; Zeuzem, S | 1 |
Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S | 1 |
Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
Abdel-Kareem, RF; Abdelazim, AH; Attia, KAM; El-Olemy, A; Hasan, MA; Ramzy, S | 1 |
Chen, H; Li, C; Liang, J; Tian, J; Xiang, H | 1 |
Butterton, JR; Caro, L; Fandozzi, CM; Feng, HP; Fraser, IP; Guo, Z; Iwamoto, M; Levine, V; Panebianco, D; Prueksaritanont, T; Swearingen, D; Wolford, D; Yeh, WW | 1 |
Abdelazim, AH; Shahin, M; Zeid, AM | 1 |
Buonomo, AR; Cattaneo, L; Coppola, C; Coppola, N; De Pascalis, S; Gentile, I; Martini, S; Mercinelli, S; Messina, V; Nerilli, M; Pinchera, B; Scotto, R; Staiano, L; Stanzione, M; Stornaiuolo, G | 1 |
Booth, J; Borgia, SM; Conway, B; Cooper, C; Feld, JJ; Lee, S; Lilly, LB; Morales, H; Onofrio, FQ; Ramji, A; Sattar, I; Vachon, ML; Wong, A | 1 |
Sarrazin, C | 1 |
Buti, M; Campos, C; Cañizares, A; Carrión, JA; Castro-Iglesias, A; Costa, JG; Esteban, JI; Garcia-Cehic, D; Gregori, J; Macenlle, R; Pamplona, J; Quer, J; Rando, A; Rodriguez-Frias, F; Tabernero, D | 1 |
Campo-Moneo, E; de Los Santos, I; García, F; García-Fraile, L; González-Serna, A; Granados, R; Macías, J; Merino, D; Morano, LE; Pineda, JA; Real, LM; Téllez, F; Vera-Mendez, F | 1 |
Behera, SK; Contractor, D; Jain, A; Kalia, K; Kumar, D; Shard, A; Vhora, N | 1 |
Hidaka, I; Hirao, T; Ishida, H; Sakaida, I; Suenaga, R; Suka, M | 1 |
Ciangherotti, CE; Orozco, CA; Suarez-Torres, JD | 1 |
Brotherton, AL; Garrett, KL; Noska, AJ; Shah, RB | 1 |
Abidi, SH; Ali, S; Allemailem, KS; Almansour, NM; Amerzhanov, D; Ibrahim, MAA; la Fleur, P; Lukac, M; Rafaqat, W | 1 |
Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S | 1 |
Begum, F; Ray, U; Srivastava, AK | 1 |
Abdouljoud, M; Agopian, VG; Akoad, ME; Anderson, MP; Anderson, MS; Aucejo, F; Cameron, A; Cannon, RM; Chapman, WC; Chavarriaga, A; Delman, AM; Dhanireddy, K; Doyle, M; Emamaullee, J; Esquivel, CO; Feizpour, CA; Foley, DP; Ganesh, SR; Humar, A; Kazimi, MM; Kim, A; Kim, SC; Kubal, CA; Locke, JE; Magliocca, JF; Maithel, SK; Moris, D; Moro, A; Nguyen, MH; Olyaei, A; Orloff, SL; Salgia, RJ; Shah, SA; Simpson, MA; Sonnenday, CJ; Subramanian, V; Sudan, DL; Tran, BV; Turgeon, MK; Vagefi, PA; Wedd, JP; Wongjirad, CP | 1 |
Chang, WC; Chen, HW; Hsieh, TY; Lin, JC | 1 |
Flamm, SL; Martin, MT; Patel, S | 1 |
Calvaruso, V; Ceccherini-Silberstein, F; Craxì, A; Di Maio, VC; Di Marco, V; Ferraro, D; Gibilaro, G; La Mantia, C; Licata, A; Petta, S; Reina, G | 1 |
Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H | 1 |
Chen, CH; Cheng, SB; Jeng, LB; Lai, PC; Lee, TY; Tsai, SF; Wu, MJ; Yang, SS; Yu, TM | 1 |
Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L | 1 |
Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F | 1 |
Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
Guo, M; Ke, L; Liu, J; You, R | 1 |
Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW | 1 |
Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ | 1 |
Falade-Nwulia, O; Karimi-Sari, H; Lim, JK; Rezaee-Zavareh, MS | 1 |
Butt, ZA | 1 |
38 review(s) available for quinoxalines and carbamates
Article | Year |
---|---|
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.
Topics: Amides; Animals; Carbamates; Clinical Trials as Topic; Cyclopropanes; Hepatitis C; Humans; Protease Inhibitors; Quinoxalines; Sulfonamides; Treatment Outcome | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Discovery; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Indoles; Isoquinolines; MicroRNAs; Molecular Targeted Therapy; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Nonstructural Proteins | 2015 |
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2016 |
Hepatitis C virus: how to provide the best treatment with what I have.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult | 2016 |
Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2016 |
New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
Topics: Amides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Quinoxalines; Renal Insufficiency; Sulfonamides; Treatment Outcome | 2017 |
Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Protease Inhibitors; Quinoxalines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sulfonamides | 2016 |
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Cyclopropanes; Drugs, Investigational; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Quinoxalines; Sofosbuvir; Sulfonamides | 2016 |
Elbasvir/grazoprevir (Zepatier) for hepatitis C.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Fatigue; Hepatitis C; Humans; Imidazoles; Nausea; Quinoxalines; Sulfonamides | 2016 |
Elbasvir/Grazoprevir: First Global Approval.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Protease Inhibitors; Quinoxalines; Sulfonamides | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Quinoxalines; Republic of Korea; Sofosbuvir; Sulfonamides | 2016 |
Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2016 |
Grazoprevir/elbasvir fixed-dose combination for hepatitis C.
Topics: Amides; Animals; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2016 |
Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection.
Topics: Amides; Animals; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2017 |
Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Quinoxalines; Ribavirin; Sulfonamides; Transplant Recipients | 2016 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine | 2017 |
NewDrugs 2017, part 2.
Topics: Amides; Antibodies, Monoclonal, Humanized; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Therapy; gamma-Cyclodextrins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Peptides; Phenylalanine; Quinoxalines; Sofosbuvir; Sugammadex; Sulfonamides; Sulfones; Thioglycolates; Triazoles; United States; United States Food and Drug Administration | 2017 |
Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.
Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets; Treatment Outcome | 2017 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2018 |
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2019 |
Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Molecular Conformation; Quinoxalines; Sulfonamides | 2018 |
Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Expert opinion on the management of renal manifestations of chronic HCV infection.
Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Disease Management; Drug Therapy, Combination; Expert Testimony; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Practice Guidelines as Topic; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Risk Factors; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Treatment of hepatitis C virus genotype 4 in the DAA era.
Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Topics: 2-Naphthylamine; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Denmark; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Prognosis; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Uracil; Valine | 2019 |
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2019 |
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2019 |
Overview of hepatitis C infection, molecular biology, and new treatment.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2020 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
Topics: Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2020 |
Treatment failure with DAA therapy: Importance of resistance.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2021 |
Elbasvir/grazoprevir administered for 12 weeks via percutaneous endoscopic gastrostomy tube achieves sustained virologic response: A case report and a review of the literature.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Gastrostomy; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides | 2022 |
57 trial(s) available for quinoxalines and carbamates
Article | Year |
---|---|
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2014 |
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
Topics: Amides; Carbamates; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Interferons; Quinoxalines; Ribavirin; Sulfonamides | 2014 |
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2015 |
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2015 |
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Nausea; Quinoxalines; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2015 |
Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
Topics: Adult; Aged; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Salvage Therapy; Sulfonamides; Treatment Outcome | 2016 |
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Topics: Adult; Amides; Antiviral Agents; Australia; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; RNA, Viral; Sulfonamides; Treatment Outcome; United States; Viral Load | 2015 |
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
Topics: Aged; Amides; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Renal Insufficiency, Chronic; RNA, Viral; Sulfonamides; Treatment Outcome | 2015 |
[High chance of healing for opiate dependent patients].
Topics: Amides; Benzofurans; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Medication Adherence; Opiate Substitution Treatment; Opioid-Related Disorders; Quinoxalines; Substance Abuse, Intravenous; Sulfonamides | 2016 |
[New therapy option in the pipeline].
Topics: Administration, Oral; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2016 |
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Protease Inhibitors; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult | 2016 |
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Young Adult | 2017 |
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2017 |
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2017 |
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Topics: Administration, Oral; Adult; Amides; Benzofurans; Biopsy, Needle; Blood Coagulation Disorders, Inherited; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunohistochemistry; Liver Function Tests; Male; Middle Aged; Quinoxalines; Reference Values; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2017 |
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Young Adult | 2017 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2017 |
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
Topics: Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Quinoxalines; Renal Insufficiency, Chronic; Sulfonamides; Sustained Virologic Response | 2017 |
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2,
Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Thiazoles; Uridine | 2017 |
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Thiazoles; Uridine; Young Adult | 2017 |
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Sulfonamides; Young Adult | 2017 |
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2018 |
IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interleukins; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2017 |
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2018 |
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Internationality; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Young Adult | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Graft Rejection; Graft Survival; Hepatitis C; Humans; Imidazoles; Kidney; Kidney Transplantation; Male; Middle Aged; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Tissue Donors; Treatment Outcome | 2018 |
A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.
Topics: Adult; Amides; Antiviral Agents; Asian People; Benzofurans; Carbamates; Cyclopropanes; Female; Humans; Imidazoles; Male; Quinoxalines; Sulfonamides; Young Adult | 2018 |
Efficacy and Safety of Elbasvir-Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real-Life Clinical Practice.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Sulfonamides | 2018 |
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2018 |
Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Linear Models; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Data Interpretation, Statistical; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Predictive Value of Tests; Quinoxalines; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sustained Virologic Response; Viral Load | 2019 |
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Topics: Adult; Amides; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzofurans; Carbamates; Chromatography, Liquid; Coinfection; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Imidazoles; Male; Mass Spectrometry; Middle Aged; Oxazines; Piperazines; Pyridones; Quinoxalines; Raltegravir Potassium; Sulfonamides; Treatment Outcome; Young Adult | 2019 |
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
Topics: Acute Disease; Administration, Oral; Adult; Amides; Antiviral Agents; Belgium; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Incidence; Male; Middle Aged; Netherlands; Quinoxalines; Sexually Transmitted Diseases; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Failure; Treatment Outcome | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Topics: Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Quinoxalines; Renal Dialysis; Sulfonamides | 2019 |
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia | 2019 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Graft Rejection; Heart Failure; Heart Transplantation; Heart-Assist Devices; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Postoperative Period; Quinoxalines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Tissue and Organ Procurement; Treatment Outcome; Viral Load; Waiting Lists | 2019 |
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; RNA, Viral; Severity of Illness Index; Sulfonamides; Sustained Virologic Response | 2019 |
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2020 |
Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Genotype; Hepacivirus; Hepatitis C, Chronic; Homosexuality, Male; Humans; Imidazoles; Male; Quality of Life; Quinoxalines; RNA, Viral; Sexual and Gender Minorities; Sulfonamides | 2020 |
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Topics: Adult; Aged; Amides; Antiviral Agents; Asia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides | 2020 |
Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.
Topics: Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides; Tablets | 2020 |
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Proteins; Pravastatin; Quinolines; Quinoxalines; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2021 |
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Death, Sudden; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Rwanda; Sofosbuvir; Sulfonamides; Treatment Failure | 2022 |
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
130 other study(ies) available for quinoxalines and carbamates
Article | Year |
---|---|
[Toxicity by relay. II. A method for the asessment of safety to human consumers of carbadox, a growth-promoting additive to the feed of slaughter pigs].
Topics: Animal Feed; Animals; Anti-Infective Agents; Body Weight; Carbamates; Diet; Dogs; Dose-Response Relationship, Drug; Estrus; Female; Fertility; Fetus; Food Additives; Growth Substances; Male; Meat; Methods; Potassium; Pregnancy; Quinoxalines; Rats; Reproduction; Sodium; Species Specificity; Swine; Time Factors | 1975 |
Detection of naturally fluorescent pesticides on silica gel layers.
Topics: Benzimidazoles; Carbamates; Chromatography, Thin Layer; Coumarins; Dicarboxylic Acids; Dioxoles; Environmental Pollution; Fluorometry; Food Contamination; Fungicides, Industrial; Gels; Hot Temperature; Methods; Naphthalenes; Organothiophosphorus Compounds; Pesticide Synergists; Pesticides; Phenindione; Quinoxalines; Silicon Dioxide; Sulfides | 1973 |
Spectrophotometric determination of carbadox in swine feeds.
Topics: Animal Feed; Animals; Anti-Infective Agents; Carbamates; Chromatography; Food Additives; Quinoxalines; Solubility; Solvents; Spectrum Analysis; Swine | 1974 |
Efficacy of carbadox in prevention of field outbreaks of swine dysentery.
Topics: Animals; Anti-Infective Agents; Carbamates; Disease Outbreaks; Dysentery; Quinoxalines; Swine; Swine Diseases | 1973 |
Therapeutic efficacy of carbadox in field outbreaks of swine dysentery.
Topics: Animals; Anti-Infective Agents; Carbamates; Disease Outbreaks; Dysentery; Female; Male; Quinoxalines; Swine; Swine Diseases | 1973 |
Carbadox: a new feed additive for pigs.
Topics: Animals; Body Weight; Carbamates; Food Additives; Quinoxalines; Swine | 1972 |
Quinoxaline precursors of fungitoxic benzimidazolycarbamates: syntheses and photochemically-induced transformations.
Topics: Antifungal Agents; Benzimidazoles; Carbamates; Light; Methods; Mycotoxins; Oxides; Photochemistry; Quinoxalines; Radiation Effects | 1973 |
Effect of carbadox in experimentally induced salmonellosis of swine.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Body Temperature; Body Weight; Carbamates; Colitis; Diarrhea; Female; Male; Quinoxalines; Salmonella; Salmonella Infections, Animal; Swine; Swine Diseases | 1974 |
Evaluation of 5500 young pigs of Carbadox used at 50 ppm. Economic interpretation in reference with performances of control animals or supplements used at nutritional (less than or equal to 150 ppm) or therapeutic (greater than or equal to 200 ppm) levels
Topics: Animal Feed; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Body Weight; Carbamates; Costs and Cost Analysis; Quinoxalines; Sulfamethazine; Swine | 1974 |
Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor.
Topics: Animals; Carbamates; Cells, Cultured; GABA Antagonists; Imidazoles; Quinoxalines; Rats; Receptors, GABA; Stereoisomerism; Structure-Activity Relationship | 1994 |
Presenilin attenuates receptor-mediated signaling and synaptic function.
Topics: Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Carbamates; Carbazoles; Cell Adhesion Molecules; Cell Line, Tumor; Cell Membrane; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; DCC Receptor; Dipeptides; Endopeptidases; Excitatory Postsynaptic Potentials; Genes, DCC; Glutamic Acid; Indoles; Lidocaine; Membrane Proteins; Memory; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurites; Neuroblastoma; Neurons; Piperazines; Presenilin-1; Protein Processing, Post-Translational; Pyrroles; Quinoxalines; Rats; Receptors, Cell Surface; Recombinant Fusion Proteins; Second Messenger Systems; Synaptic Transmission; Transfection; Tumor Suppressor Proteins | 2005 |
Depolarizing GABAergic synaptic input triggers endocannabinoid-mediated retrograde synaptic signaling.
Topics: Aniline Compounds; Animals; Animals, Newborn; Arachidonic Acids; Benzamides; Bicuculline; Biophysics; Calcium; Calcium Signaling; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Carbamates; Cerebellum; Electric Stimulation; Endocannabinoids; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Fluoresceins; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Glycerides; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Lactones; Mice; Muscimol; Orlistat; Patch-Clamp Techniques; Piperidines; Purkinje Cells; Pyrazoles; Quinoxalines; Rimonabant; Signal Transduction; Synapses; Valine | 2009 |
Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer's disease.
Topics: Aged; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Benzazepines; Carbamates; Cell Line, Tumor; Cells, Cultured; Frontal Lobe; Humans; Neurons; Nicotinic Agonists; PC12 Cells; Quinoxalines; Quinuclidines; Rats; Receptors, Nicotinic; Varenicline | 2011 |
Multiresidue method for the determination of 13 pesticides in three environmental matrices: water, sediments and fish muscle.
Topics: Acetamides; Aminoimidazole Carboxamide; Animals; Benzimidazoles; Carbamates; Chemical Fractionation; Chromatography, Liquid; Environmental Monitoring; Fishes; Geologic Sediments; Hydantoins; Isoxazoles; Methacrylates; Muscles; Naphthalenes; Niacinamide; Oxazolidinones; Pesticide Residues; Pesticides; Phenylurea Compounds; Propionates; Pyrimidines; Quinoxalines; Reproducibility of Results; Solid Phase Extraction; Strobilurins; Sulfonylurea Compounds; Tandem Mass Spectrometry; Thiophenes; Water Pollutants, Chemical | 2011 |
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
Topics: Amides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Dogs; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Liver; Pan troglodytes; Protease Inhibitors; Quinoxalines; Rats; Sulfonamides; Viral Load; Viral Nonstructural Proteins | 2012 |
Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Molecular Dynamics Simulation; Mutation; Proline; Protease Inhibitors; Protein Conformation; Quinoxalines; Sulfonamides; Thermodynamics; Viral Nonstructural Proteins | 2014 |
Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172.
Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Macrocyclic Compounds; Molecular Structure; Protease Inhibitors; Quinoxalines; Sulfonamides | 2013 |
New kids on the block--step by step to an ideal HCV therapy.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides | 2015 |
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Treatment Failure | 2015 |
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.
Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides | 2015 |
Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.
Topics: Amides; Amino Acid Substitution; Antiviral Agents; Carbamates; Cell Line; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; Oligopeptides; Protease Inhibitors; Quinoxalines; Recombinant Proteins; Sulfonamides; Viral Nonstructural Proteins | 2015 |
Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172.
Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Quinoxalines; Sulfonamides; Thermodynamics; Viral Nonstructural Proteins | 2016 |
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Imidazoles; Mutation; Protease Inhibitors; Quinoxalines; Replicon; Ribavirin; Sulfonamides | 2016 |
The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
Topics: Administration, Oral; Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Polymorphism, Genetic; Predictive Value of Tests; Quinoxalines; Sulfonamides; United States; Viral Nonstructural Proteins; Virology | 2017 |
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Computer Simulation; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Quinoxalines; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; United States | 2017 |
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
Topics: Amides; Antiviral Agents; Asthenia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Load | 2017 |
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Randomized Controlled Trials as Topic; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult | 2017 |
Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
Topics: Amides; Amino Acid Substitution; Carbamates; Cell Line, Tumor; Cyclopropanes; Hepacivirus; Hepatitis C; Humans; Molecular Dynamics Simulation; Mutation, Missense; Quinoxalines; Simeprevir; Sulfonamides; Viral Nonstructural Proteins | 2017 |
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Contraceptives, Oral, Combined; Cyclopropanes; Drug Interactions; Ethinyl Estradiol; Female; Hepacivirus; Humans; Imidazoles; Levonorgestrel; Middle Aged; Quinoxalines; Sulfonamides; Young Adult | 2017 |
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Macrocyclic Compounds; Male; Patient Participation; Patient-Centered Care; Prospective Studies; Pyrrolidines; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2017 |
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2017 |
Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Lipids; Male; Middle Aged; Quinoxalines; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2018 |
Preclinical and clinical properties of elbasvir (ERELSA
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Evaluation, Preclinical; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Quinoxalines; Sulfonamides; Virus Activation | 2017 |
Application of different spectrophotometric methods for simultaneous determination of elbasvir and grazoprevir in pharmaceutical preparation.
Topics: Algorithms; Amides; Benzofurans; Calibration; Carbamates; Cyclopropanes; Drug Compounding; Imidazoles; Least-Squares Analysis; Quinoxalines; Reference Standards; Regression Analysis; Reproducibility of Results; Spectrophotometry; Sulfonamides | 2018 |
Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
Topics: Adult; Aged; Aged, 80 and over; Amides; Anti-Retroviral Agents; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Combined Modality Therapy; Cross-Sectional Studies; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Imidazoles; Middle Aged; Quinoxalines; Retrospective Studies; Ritonavir; Sulfonamides; Young Adult | 2017 |
Mavyret and Vosevi--two new combinations for chronic HCV infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2017 |
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
New Oral HCV Drug.
Topics: Administration, Oral; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Contraindications, Drug; Cyclopropanes; Drug Approval; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Placebos; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Surveys and Questionnaires; Sustained Virologic Response | 2018 |
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Self Report; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2018 |
Biochemical Basis of Vosevi, a New Treatment for Hepatitis C
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2018 |
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.
Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Cyclopropanes; Female; Humans; Imidazoles; Liver Diseases; Male; Middle Aged; Quinoxalines; Sulfonamides | 2018 |
New Drugs 2018, part 1.
Topics: Aminoisobutyric Acids; Antibodies, Monoclonal; Antibodies, Neutralizing; Antipyrine; Benzamides; Benzimidazoles; Broadly Neutralizing Antibodies; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Edaravone; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Naltrexone; Natriuretic Peptides; Proline; Pyridines; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Viral Load; Viral Nonstructural Proteins; Young Adult | 2018 |
Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Quinoxalines; Randomized Controlled Trials as Topic; Renal Dialysis; RNA, Viral; Sulfonamides | 2018 |
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Topics: Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Japan; Male; Middle Aged; Multivariate Analysis; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response | 2018 |
Simultaneous Determination of Elbasvir and Grazoprevir in Their Pharmaceutical Preparation Using High-Performance Liquid Chromatographic Method.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Combinations; Imidazoles; Limit of Detection; Models, Molecular; Pharmaceutical Preparations; Quinoxalines; Sulfonamides; Tablets | 2018 |
Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; United States; Veterans | 2018 |
Retreatment of hepatitis C virus: can it get any better?
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2018 |
Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Gastrostomy; Hepatitis C, Chronic; Humans; Imidazoles; Male; Quinoxalines; Sulfonamides | 2018 |
Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Goals; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2018 |
Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease-Author's reply.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Diseases; Quinoxalines; Retrospective Studies; Sulfonamides | 2018 |
Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Diseases; Quinoxalines; Retrospective Studies; Sulfonamides | 2018 |
Hepatitis C virus infection: 'beyond the liver'.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Dermatomyositis; Diagnosis, Differential; Female; Hepatitis C; Humans; Imidazoles; Quinoxalines; Sulfonamides; Viral Load | 2018 |
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
Topics: Amides; Benzofurans; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Hepacivirus; HIV; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Quinoxalines; Ribavirin; Sexual and Gender Minorities; Sulfonamides | 2019 |
Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.
Topics: Amides; Amino Acid Substitution; Antiviral Agents; Carbamates; Catalytic Domain; Crystallography, X-Ray; Cyclopropanes; Drug Resistance, Multiple, Viral; Hepacivirus; Humans; Models, Molecular; Molecular Dynamics Simulation; Mutation; Protease Inhibitors; Protein Conformation; Quinoxalines; Sulfonamides; Viral Nonstructural Proteins | 2018 |
Topics: Amides; Antiviral Agents; Carbamates; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Protease Inhibitors; Pyrrolidines; Quinoxalines; Replicon; Sulfonamides; Thiazoles; Uridine; Viral Nonstructural Proteins | 2018 |
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sulfonamides; Valine | 2018 |
Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Renal Insufficiency, Chronic; RNA, Viral; Sulfonamides; Sustained Virologic Response; Young Adult | 2018 |
Synthesis of Grazoprevir, a Potent NS3/4a Protease Inhibitor for the Treatment of Hepatitis C Virus.
Topics: Amides; Antiviral Agents; Carbamates; Cyclization; Cyclopropanes; Hepacivirus; Molecular Structure; Quinoxalines; Serine Proteases; Sulfonamides; Viral Nonstructural Proteins | 2018 |
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
Topics: Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Dialysis; Retreatment; Sulfonamides; Treatment Failure; Valine | 2019 |
Management of acute HCV in the era of direct-acting antivirals: implications for elimination.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2019 |
Hemoprotein-Catalyzed Cyclopropanation En Route to the Chiral Cyclopropanol Fragment of Grazoprevir.
Topics: Alkenes; Amides; Azo Compounds; Bacterial Proteins; Biocatalysis; Carbamates; Cyclization; Cyclopropanes; Directed Molecular Evolution; Hemeproteins; Molecular Structure; Mutagenesis, Site-Directed; Proof of Concept Study; Propanols; Quinoxalines; Sulfonamides; Verrucomicrobia | 2019 |
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Topics: Adult; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Fluorenes; Humans; Imidazoles; Least-Squares Analysis; Male; Middle Aged; Pyridones; Quinoxalines; Sulfonamides; Triazoles | 2019 |
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
Topics: Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Load | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2019 |
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Proline; Prospective Studies; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
Possibilities and Limiting Factors for the Use of Dissolution as a Quality Control Tool to Detect Presence of Crystallinity for Amorphous Solid Dispersions: An Experimental and Modeling Investigation.
Topics: Amides; Carbamates; Chemistry, Pharmaceutical; Crystallization; Cyclopropanes; Drug Compounding; Drug Liberation; Feasibility Studies; Limit of Detection; Models, Chemical; Particle Size; Quality Control; Quinoxalines; Solubility; Sulfonamides; Tablets | 2019 |
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Republic of Korea; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2019 |
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Discovery; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Microbial Sensitivity Tests; Molecular Structure; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Structure-Activity Relationship; Sulfonamides; Viral Nonstructural Proteins | 2019 |
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Markov Chains; Proline; Quinoxalines; Sofosbuvir; State Medicine; Sulfonamides; United Kingdom | 2019 |
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Quinoxalines; Ribavirin; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2019 |
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Phosphoproteins; Pyrrolidines; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Load; Viral Nonstructural Proteins | 2019 |
Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy.
Topics: Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon-alpha; Italy; Polypharmacy; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2019 |
Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2020 |
Simultaneous determination of elbasvir and grazoprevir in fixed-dose combination and mass spectral characterization of each degradation product by UHPLC-ESI-QTOF-MS/MS.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Combinations; Imidazoles; Quinoxalines; Sulfonamides; Tandem Mass Spectrometry | 2020 |
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Comorbidity; Cyclopropanes; Data Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Renal Insufficiency, Chronic; Retrospective Studies; Sex Factors; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2020 |
Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection.
Topics: Adolescent; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cell Line, Tumor; Culture Media; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Microbial Sensitivity Tests; Mutation; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2020 |
Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to Dramatic Underestimation of Liver Function With 99mTc-Mebrofenin Hepatobiliary Scintigraphy.
Topics: Adult; Amides; Aniline Compounds; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Glycine; Hepacivirus; Humans; Imidazoles; Imino Acids; Liver Failure; Organotechnetium Compounds; Quinoxalines; Radionuclide Imaging; Radiopharmaceuticals; Sulfonamides | 2020 |
Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Electronic Health Records; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sulfonamides; United States; Veterans; Young Adult | 2020 |
Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Catalytic Domain; Crystallography, X-Ray; Cyclopropanes; Hepacivirus; Lactams, Macrocyclic; Leucine; Mutation; Proline; Protein Binding; Quinoxalines; Serine Proteases; Serine Proteinase Inhibitors; Sulfonamides; Viral Nonstructural Proteins | 2020 |
Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Monitoring; Female; Half-Life; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets | 2020 |
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2020 |
Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Middle Aged; Peritoneal Dialysis; Quinoxalines; Sulfonamides; Sustained Virologic Response | 2020 |
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response | 2021 |
Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.
Topics: Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Duration of Therapy; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Quinoxalines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors | 2020 |
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult | 2020 |
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Republic of Korea; Retrospective Studies; Sulfonamides | 2021 |
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Treatment Failure | 2020 |
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
Topics: Amides; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Binding Sites; Caffeic Acids; Carbamates; Coronavirus Infections; Coumaric Acids; COVID-19; Cyclopropanes; Doxycycline; Gene Expression; Humans; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Nucleocapsid Proteins; Pandemics; Pneumonia, Viral; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Quinoxalines; Rutin; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Simeprevir; Sulfonamides; Thermodynamics; Viral Envelope Proteins; Viral Matrix Proteins; Virion | 2020 |
Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.
Topics: Amides; Betacoronavirus; Carbamates; Catalytic Domain; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cyclopropanes; Dimerization; Drug Design; Drug Repositioning; Humans; Molecular Docking Simulation; Pandemics; Pneumonia, Viral; Protease Inhibitors; Quinoxalines; Rimantadine; SARS-CoV-2; Sulfonamides; Viral Proteins | 2020 |
Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2021 |
Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
Topics: Amides; Antiviral Agents; Benzofurans; Biomarkers; Carbamates; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; MicroRNAs; Oligonucleotide Array Sequence Analysis; Pyrrolidines; Quinoxalines; Sulfonamides; Valine | 2021 |
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Quinoxalines; Sulfonamides | 2020 |
Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients.
Topics: Adult; Alanine Transaminase; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2020 |
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response | 2022 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine | 2021 |
Simultaneous determination of elbasvir and grazoprevir in their pharmaceutical formulation by synchronous fluorescence spectroscopy coupled to dual wavelength method.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Compounding; Imidazoles; Quinoxalines; Spectrometry, Fluorescence; Sulfonamides; Tablets | 2021 |
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
Topics: Alanine Transaminase; Amides; Antiviral Agents; Aspartate Aminotransferases; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2020 |
Simultaneous spectrophotometric quantitative analysis of elbasvir and grazoprevir using assisted chemometric models.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Humans; Imidazoles; Quinoxalines; Spectrophotometry; Sulfonamides | 2021 |
Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results.
Topics: Adult; Age Distribution; Aged; Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Italy; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response | 2021 |
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Canada; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Registries; Salvage Therapy; Sofosbuvir; Sulfonamides | 2021 |
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2021 |
Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.
Topics: Amides; Analgesics, Opioid; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pharmaceutical Preparations; Prospective Studies; Quinoxalines; Sulfonamides | 2021 |
Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir.
Topics: Amides; Angiotensin-Converting Enzyme 2; Antiviral Agents; Carbamates; Coronavirus RNA-Dependent RNA Polymerase; Cyclopropanes; Drug Repositioning; Humans; Models, Molecular; Molecular Dynamics Simulation; Quinoxalines; Serine Endopeptidases; Sulfonamides; Virus Internalization | 2021 |
Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Young Adult | 2021 |
The numerical probability of carcinogenicity to humans of some antimicrobials: Nitro-monoaromatics (including 5-nitrofurans and 5-nitroimidazoles), quinoxaline-1,4-dioxides (including carbadox), and chloramphenicol.
Topics: Animals; Anti-Infective Agents; Biological Assay; Carbamates; Carcinogens; Humans; Nitro Compounds; Predictive Value of Tests; Probability; Quinoxalines; Risk Assessment | 2021 |
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.
Topics: Amides; Antiviral Agents; Carbamates; COVID-19 Drug Treatment; Cyclopropanes; Drug Repositioning; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Domains; Quinoxalines; RNA Helicases; SARS-CoV-2; Sulfonamides; Triazoles; Viral Proteins | 2021 |
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight.
Topics: Amides; Antiviral Agents; Benzimidazoles; Carbamates; Catalytic Domain; Computer Simulation; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Cyclopropanes; Drug Evaluation, Preclinical; Drug Repositioning; Fluorenes; Humans; Lactams, Macrocyclic; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Proline; Protein Conformation; Quinoxalines; SARS-CoV-2; Sulfonamides | 2021 |
Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Quinoxalines; Retrospective Studies; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Successful treatment of chronic hepatitis C virus infection with crushed elbasvir/grazoprevir administered through a nasogastric tube in a patient with hypoxic encephalopathy.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoxia, Brain; Imidazoles; Intubation, Gastrointestinal; Middle Aged; Quinoxalines; Sulfonamides | 2022 |
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2021 |
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA; Sulfonamides | 2022 |
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome | 2022 |
Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Middle Aged; Quinoxalines; Sulfonamides | 2022 |
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome | 2022 |
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome | 2022 |
Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder.
Topics: Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Opioid-Related Disorders; Quinoxalines; Sulfonamides | 2022 |